Cipla

Cipla | December 15, 2016

Cipla, through its Netherlands-based wholly-owned subsidiary Cipla Holding BV, has entered into an agreement with Ahran Tejarat Company to form a joint venture in Iran. As per the agreement, Cipla will hold 75 percent stake in the JV, while the Iranian partner will own the remaining. Cipla will invest approximately Euro 16.875 million (about Rs 120 crore) in the JV, which JV will set up a manufacturing facility for pharmaceutical products in Iran....

Pharmaphorum Media Limited | February 19, 2019

Indian pharma company Cipla has made another play in the digital medicine category by taking a near-12% stake in start-up Wellthy Therapeutics. Under the terms of their agreement Wellthy and Cipla – which is India’s third-biggest pharma company – will work together on combined drug and digital therapies for type 2 diabetes as well as for patients with cardiovascular disease. Cipla is paying around 105 million rupees ($1.5 million) for its stake in Wellthy. The aim is to offer &...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...